Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The role of radiotherapy in metastatic prostate cancer.

Khullar K, Parikh RR.

Am J Clin Exp Urol. 2019 Apr 25;7(2):92-97. eCollection 2019. Review.

2.

Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, Everaerts W, Joniau S.

Eur Urol Oncol. 2019 Mar;2(2):174-188. doi: 10.1016/j.euo.2018.09.005. Epub 2018 Oct 9. Review.

PMID:
31017094
3.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
4.

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F.

BMC Cancer. 2015 Sep 25;15:646. doi: 10.1186/s12885-015-1579-0.

5.

Contemporary role of androgen deprivation therapy for prostate cancer.

Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE.

Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Review.

6.

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.

Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C.

Eur Urol. 2018 Jun;73(6):847-855. doi: 10.1016/j.eururo.2018.02.001. Epub 2018 Feb 21.

7.

[Radiotherapy for local disease in metastatic prostate cancer.]

Cambeiro M, Calvo FA.

Arch Esp Urol. 2018 Mar;71(3):298-305. Review. Spanish.

PMID:
29633951
8.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG.

Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21.

PMID:
26610858
9.

Advances in local and ablative treatment of oligometastasis in prostate cancer.

Yao HH, Hong MKh, Corcoran NM, Siva S, Foroudi F.

Asia Pac J Clin Oncol. 2014 Dec;10(4):308-21. doi: 10.1111/ajco.12256. Epub 2014 Aug 25. Review.

PMID:
25155557
10.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
11.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
12.

A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?

Slaoui A, Albisinni S, Aoun F, Assenmacher G, Al Hajj Obeid W, Diamand R, Regragui S, Touzani A, Bakar A, Mesfioui A, Karmouni T, Ameur A, Elkhader K, Koutani A, Ibnattya A, Roumeguere T, Peltier A.

World J Urol. 2019 Jan 31. doi: 10.1007/s00345-019-02652-7. [Epub ahead of print]

PMID:
30706122
13.

The oncologic role of local treatment in primary metastatic prostate cancer.

Ghadjar P, Briganti A, De Visschere PJ, Fütterer JJ, Giannarini G, Isbarn H, Ost P, Sooriakumaran P, Surcel CI, van den Bergh RC, van Oort IM, Yossepowitch O, Ploussard G.

World J Urol. 2015 Jun;33(6):755-61. doi: 10.1007/s00345-014-1347-9. Epub 2014 Jul 5. Review.

PMID:
24997127
14.

Radiotherapy and Hormone Treatment in Prostate Cancer.

Böhmer D, Wirth M, Miller K, Budach V, Heidenreich A, Wiegel T.

Dtsch Arztebl Int. 2016 Apr 8;113(14):235-41. doi: 10.3238/arztebl.2016.0235. Review.

15.

The role of radiotherapy in node-positive prostate cancer.

Baker BR, Mohiuddin JJ, Chen RC.

Oncology (Williston Park). 2015 Feb;29(2):108-14, 116. Review.

16.

Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.

Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD.

Urol Oncol. 2016 Apr;34(4):165.e1-9. doi: 10.1016/j.urolonc.2015.11.004. Epub 2015 Dec 11.

PMID:
26699831
17.
18.

Androgen deprivation therapy as backbone therapy in the management of prostate cancer.

Merseburger AS, Alcaraz A, von Klot CA.

Onco Targets Ther. 2016 Nov 29;9:7263-7274. eCollection 2016. Review.

19.

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.

Kim J, Park JS, Ham WS.

Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8. Review.

20.

The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.

Gunner C, Gulamhusein A, Rosario DJ.

J Clin Urol. 2016 Dec;9(2 Suppl):24-29. doi: 10.1177/2051415816654048. Epub 2016 Dec 1.

Supplemental Content

Support Center